Chemotherapy News and Research

Latest Chemotherapy News and Research

People with blood-related cancers more likely to experience COVID breakthrough infections

Individuals with blood-related cancers are more likely to experience a COVID-19 infection even after being vaccinated, a University of Kansas Cancer Center study has found.

12 Aug 2022

Experts aim to relieve children from the side-effects of cancer treatments

Stopping children undergoing chemotherapy from feeling pain and other debilitating side-effects is the focus of research underway at The University of Queensland.

12 Aug 2022

OICR funding to help five research projects take the next step toward advancing cancer care

Five Ontario-based research projects will take the next step toward advancing cancer care in the province thanks to funding from the Ontario Institute for Cancer Research (OICR).

11 Aug 2022

Traditional Chinese medicine reduces severity of radiation-induced gastrointestinal mucositis in rats

For tens of thousands of Australians who receive radiotherapy as part of their cancer treatment, mucositis is a serious side effect that may cause inflammation, ulcers, diarrhea, nausea and vomiting, abdominal pain and bloating.

11 Aug 2022

Research identifies unique vulnerabilities in ALT cancers that can serve as novel therapeutic targets

In a study recently published in Cancer Research, a journal of the American Association for Cancer Research, a team of researchers led by C. Patrick Reynolds, M.D., Ph.D., director for the Texas Tech University Health Sciences Center School of Medicine Cancer Center, sought to expand upon his lab's previous research that showed ALT tumors identified by a biomarker known as C-circles share a common biology that confers vulnerabilities to be exploited for cancer therapy.

10 Aug 2022

Study shows how the same protein that is key for brain development can also be the cause for the spread of cancer

Researchers at Queen's University Belfast have revealed how the pathway of an identified protein could lead to early diagnosis and targeted treatment for several cancers and brain disorders.

10 Aug 2022

Novel class of drug regresses active brain metastases in breast cancer patients

An Austrian study led by MedUni Vienna showed that active brain metastases in breast cancer patients are partially or even completely regressed by a novel class of drug. This is a chemical conjugate of an antibody and a chemotherapy drug that, according to current findings, opens up a completely new avenue in oncological research and targeted therapy.

10 Aug 2022

Researchers identify novel molecular pathway that suppresses the spread of glioblastoma

UT Southwestern researchers have identified a molecular pathway responsible for the spread of glioblastoma to surrounding tissue in the brain, as well as an existing drug that curbed tumor growth in animal models.

10 Aug 2022

MIT researchers develop an easy-to-use test to predict Covid-19 immunity

Most people in the United States have some degree of immune protection against Covid-19, either from vaccination, infection, or a combination of the two. But, just how much protection does any individual person have?

9 Aug 2022

Researchers unravel a novel molecular target of eicosapentaenoic acid

Eicosapentaenoic acid (EPA) is an essential nutrient belonging to the omega-3 group of polyunsaturated fatty acids (PUFAs). As the human body cannot synthesize PUFAs, dietary supplements containing EPA are required for normal physiological functions. Found abundantly in natural sources like fish, hemp oil, and linseed oil, EPA is known to exhibit anti-inflammatory, neuroprotective, and cardiovascular protective activities.

9 Aug 2022

Researchers synthesize a small molecule that can be used to treat a range of cancers

Researchers at Tel Aviv University and the University of Lisbon have jointly identified and synthesized a small molecule that could be a more accessible and effective alternative to an antibody that is successfully used to treat a range of cancers.

8 Aug 2022

Powerful injectable gel provides hope for preventing glioblastoma relapse

Like the hardiest weed, glioblastoma almost always springs back -; usually within months after a patient's initial brain tumor is surgically removed.

8 Aug 2022

Higher doses of CAR-T therapy achieve better survival rates for young patients with hard-to-treat B-ALL

Young people who received doses of tisagenlecleucel, a chimeric antigen receptor T cell (CAR-T) therapy, at the higher end of the FDA-approved dosing range had significantly better survival rates at one year compared with those who received lower doses within this range, according to research published today in Blood Advances.

8 Aug 2022

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Researchers from Japan today reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1-positive unresectable locally advanced non-small cell lung cancer without chemotherapy met its primary endpoint with tolerable adverse reactions.

8 Aug 2022

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

Following concurrent chemoradiation for unresectable stage III non-small cell lung cancer, both nivolumab alone and nivolumab and ipilimumab combined demonstrated improved 18- month progression-free survival compared with historical controls despite a shortened interval (6 months) of treatment.

8 Aug 2022

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

In the initial NADIM trial, neoadjuvant chemoimmunotherapy was shown to be highly effective in patients with resectable stage IIIA non-small cell lung cancer.

8 Aug 2022

Nivolumab approved for combination with fluoropyrimidine- and platinum-based combination chemotherapy

Nivolumab has recently been approved both in combination with fluoropyrimidine- and platinum-based combination chemotherapy and in combination with ipilimumab for the first-line treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma with PD-L1 expression of at least one percent. The German Institute for Quality and Efficiency in Health Care (IQWiG) now examined in two early benefit assessments whether these two combinations have an added benefit for patients in comparison with chemotherapy alone.

8 Aug 2022

Chemotherapy News and Research

Latest Chemotherapy News and Research

People with blood-related cancers more likely to experience COVID breakthrough infections

Experts aim to relieve children from the side-effects of cancer treatments

OICR funding to help five research projects take the next step toward advancing cancer care

Traditional Chinese medicine reduces severity of radiation-induced gastrointestinal mucositis in rats

Research identifies unique vulnerabilities in ALT cancers that can serve as novel therapeutic targets

Study shows how the same protein that is key for brain development can also be the cause for the spread of cancer

Novel class of drug regresses active brain metastases in breast cancer patients

Researchers identify novel molecular pathway that suppresses the spread of glioblastoma

MIT researchers develop an easy-to-use test to predict Covid-19 immunity

Researchers unravel a novel molecular target of eicosapentaenoic acid

Researchers synthesize a small molecule that can be used to treat a range of cancers

Powerful injectable gel provides hope for preventing glioblastoma relapse

Higher doses of CAR-T therapy achieve better survival rates for young patients with hard-to-treat B-ALL

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

Nivolumab approved for combination with fluoropyrimidine- and platinum-based combination chemotherapy

Five-year, $2.7 million grant could help determine the best treatment for lung cancer patients

Skin cancer is a risk no matter the skin tone. But it may be overlooked in people with dark skin.

Researchers identify a component in the intestine that plays key role in repairing damaged tissue

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in